How to buy Infinity Pharmaceuticals stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Infinity Pharmaceuticals stock

Own Infinity Pharmaceuticals stock in just a few minutes.

Infinity Pharmaceuticals, Inc is a biotechnology business based in the US. Infinity Pharmaceuticals shares (INFI) are listed on the NASDAQ and all prices are listed in US Dollars. Infinity Pharmaceuticals employs 23 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in Infinity Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Infinity Pharmaceuticals. Find the stock by name or ticker symbol: INFI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Infinity Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Infinity Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Infinity Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Infinity Pharmaceuticals share price

Use our graph to track the performance of INFI stocks over time.

Infinity Pharmaceuticals shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$0.78 - USD$5.98
50-day moving average USD$3.1646
200-day moving average USD$2.493
Wall St. target priceUSD$8.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.336

Buy Infinity Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Infinity Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Infinity Pharmaceuticals financials

Revenue TTM USD$1.7 million
Gross profit TTM USD$-26,079,000
Return on assets TTM -54.48%
Return on equity TTM -1839.35%
Profit margin 0%
Book value $0.326
Market capitalisation USD$273 million

TTM: trailing 12 months

Shorting Infinity Pharmaceuticals shares

There are currently 1.2 million Infinity Pharmaceuticals shares held short by investors – that's known as Infinity Pharmaceuticals's "short interest". This figure is 16.9% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting Infinity Pharmaceuticals shares can be evaluated.

Infinity Pharmaceuticals's "short interest ratio" (SIR)

Infinity Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Infinity Pharmaceuticals shares currently shorted divided by the average quantity of Infinity Pharmaceuticals shares traded daily (recently around 2.4 million). Infinity Pharmaceuticals's SIR currently stands at 0.5. In other words for every 100,000 Infinity Pharmaceuticals shares traded daily on the market, roughly 500 shares are currently held short.

However Infinity Pharmaceuticals's short interest can also be evaluated against the total number of Infinity Pharmaceuticals shares, or, against the total number of tradable Infinity Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Infinity Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Infinity Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0171% of the tradable shares (for every 100,000 tradable Infinity Pharmaceuticals shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Infinity Pharmaceuticals.

Find out more about how you can short Infinity Pharmaceuticals stock.

Infinity Pharmaceuticals share dividends

We're not expecting Infinity Pharmaceuticals to pay a dividend over the next 12 months.

Have Infinity Pharmaceuticals's shares ever split?

Infinity Pharmaceuticals's shares were split on a 1:4 basis on 12 September 2006. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Infinity Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Infinity Pharmaceuticals shares which in turn could have impacted Infinity Pharmaceuticals's share price.

Infinity Pharmaceuticals share price volatility

Over the last 12 months, Infinity Pharmaceuticals's shares have ranged in value from as little as $0.78 up to $5.98. A popular way to gauge a stock's volatility is its "beta".

INFI.US volatility(beta: 2.31)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Infinity Pharmaceuticals's is 2.31. This would suggest that Infinity Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Infinity Pharmaceuticals overview

Infinity Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site